Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice

INTRODUCTION: Alzheimer's disease (AD) is the most common form of dementia. Beta‐secretase (BACE) inhibitors have been proposed as potential therapeutic interventions; however, initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease. Whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Oblak, Adrian L., Cope, Zackary A., Quinney, Sara K., Pandey, Ravi S., Biesdorf, Carla, Masters, Andi R., Onos, Kristen D., Haynes, Leslie, Keezer, Kelly J., Meyer, Jill A., Peters, Jonathan S., Persohn, Scott A., Bedwell, Amanda A., Eldridge, Kierra, Speedy, Rachael, Little, Gabriela, Williams, Sean‐Paul, Noarbe, Brenda, Obenaus, Andre, Sasner, Michael, Howell, Gareth R., Carter, Gregory W., Williams, Harriet, Lamb, Bruce T., Territo, Paul R., Sukoff Rizzo, Stacey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281365/
https://www.ncbi.nlm.nih.gov/pubmed/35846156
http://dx.doi.org/10.1002/trc2.12317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281365/
https://www.ncbi.nlm.nih.gov/pubmed/35846156
http://dx.doi.org/10.1002/trc2.12317

Ejemplares similares